TREVI THERAPEUTICS INC has a total of 66 patent applications. It decreased the IP activity by 90.0%. Its first patent ever was published in 2013. It filed its patents most often in United States, Australia and WIPO (World Intellectual Property Organization). Its main competitors in its focus markets pharmaceuticals, machines and organic fine chemistry are PERNIX SLEEP INC, OPTIGENEX INC and SOMAXON PHARMACEUTICALS INC.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 14 | |
#2 | Australia | 8 | |
#3 | WIPO (World Intellectual Property Organization) | 8 | |
#4 | Canada | 7 | |
#5 | China | 5 | |
#6 | EPO (European Patent Office) | 5 | |
#7 | Republic of Korea | 5 | |
#8 | Brazil | 4 | |
#9 | Mexico | 4 | |
#10 | Israel | 2 | |
#11 | Hong Kong | 1 | |
#12 | Japan | 1 | |
#13 | New Zealand | 1 | |
#14 | Singapore | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Machines | |
#3 | Organic fine chemistry |
# | Technology | |
---|---|---|
#1 | Medical preparations | |
#2 | Therapeutic chemical compounds | |
#3 | Unspecified technologies | |
#4 | Heterocyclic compounds |
# | Name | Total Patents |
---|---|---|
#1 | Sciascia Thomas | 51 |
#2 | Hawi Amale | 24 |
#3 | Good Jennifer | 12 |
#4 | Thomas Sciascia | 9 |
#5 | Amale Hawi | 4 |
#6 | Jennifer Good | 4 |
#7 | Good Jennifer L | 2 |
Publication | Filing date | Title |
---|---|---|
US2020022974A1 | Treatment of chronic cough, breathlessness and dyspnea | |
WO2020014342A1 | Treatment of the pruritic symptoms of liver disease | |
MX2019004804A | Treatment of prurigo nodularis. | |
US2018008592A1 | Treatment of uremic pruritus | |
US2017216277A1 | Therapeutic use of nalbuphine without aquaretic effects | |
CA2981625A1 | Compounds for treating pruritic conditions | |
EP3154546A1 | Methods for treating pruritus | |
US2014350042A1 | Methods for treating pruritus | |
MX2015007518A | Methods for treating pruritus. | |
US2014179727A1 | Methods for treating pruritus | |
US2014171459A1 | Methods for treating pruritus |